We believe that combination strategies involving PD-L1/PD-1 blockade remain a priority for future research as it has the potential to elicit benefits that will revolutionize the clinical landscape for patients with pMMR/MSS cold CRC. This evidence concerns the gene CD274 and colorectal carcinoma.